Meeting
2021 ASCO Annual Meeting
Preliminary results of the abemaciclib arm in the Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A phase II platform trial using Bayesian adaptive randomization.
Authors
Eudocia Quant Lee
Dana-Farber Cancer Institute, Boston, MA
Eudocia Quant Lee , Lorenzo Trippa , Geoffrey Fell , Rifaquat Rahman , Isabel Arrillaga-Romany , Mehdi Touat , Jan Drappatz , Mary Roberta Welch , Evanthia Galanis , Manmeet Singh Ahluwalia , Howard Colman , Louis B. Nabors , Jaroslaw T. Hepel , David Schiff , David M. Meredith , E. Antonio Chiocca , David A. Reardon , Keith L. Ligon , Brian Michael Alexander , Patrick Y. Wen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Glioma
Clinical Trial Registration Number
NCT02977780
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 2014)
DOI
10.1200/JCO.2021.39.15_suppl.2014
Abstract #
2014
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Individualized screening trial of innovative glioblastoma therapy (INSIGhT).
First Author: Brian Michael Alexander
Poster
2023 ASCO Annual Meeting
A randomized, open-label, phase 2 study evaluating abemaciclib in combination with irinotecan and temozolomide in participants with relapsed or refractory Ewing sarcoma.
First Author: Gertjan VAN HAL
Poster
2023 ASCO Annual Meeting
Abemaciclib in recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC) harboring CDKN2A loss, and/or CCND1 and/or CDK6 amplification: A phase II multicenter trial.
First Author: Jerome Fayette
Poster
2022 ASCO Annual Meeting
Feasibility and conduct of INSIGhT, a platform trial of patients with glioblastoma using Bayesian adaptive randomization.
First Author: Eudocia Quant Lee